Daniel Margolis, MD, a SPORE Career Development recipient, was interviewed by Elsevier Global Medical News regarding a recent study on which he was a co-investigator. The resulting publication discussed a new form of prostate imaging that combines MRI with real-time three-dimensional ultrasound images.
MDV3100, a drug developed by UCLA and SPORE investigators, will soon be approved by the FDA for patients with advanced prostate cancer according to an article by the Prostate Cancer Foundation. SPORE Executive Committee member Owen Witte, MD, SPORE Developmental Research award recipient Michael Jung, PhD, and SPORE Project II Co-Leader Charles Sawyers, MD began work on the drug in 2002.
You are what you eat: Low-fat diet with fish oil slows growth of prostate cancer cells. William Aronson, MD was the first author of the study with R. James Barnard, PhD, Susanne Henning, PhD, RD, David Heber, MD, PhD, David Elashoff, PhD, Jonathan Said, MD, and Pinchas Cohen, MD as co-authors. This study was covered by UCLA Media, MedIndia.com, Zee News, United Press International, MLive.com, MSN India, eCancer.com, Times of India, Khaleej Times, Asian News International, Daily Mail (UK), Contra Costa Times, HealthCanal.com, Examiner.com, Medical Xpress, Press Association, Science Daily, and the Los Angeles Daily News. Canyon News reported on the story on November 6th with Modern Medicine reporting November 10th. OncologyNurseAdvisor published the story December 16th.
Researchers develop system that finds prostate cancer metastases earlier (Lily Wu, MD, PhD was the senior author of this study). This study was covered in a large number of media outlets including UCLA Newsroom, Imperial Valley News, HealthCanal.com, News Medical, TopNews, MedIndia.com, Newspoint South Africa, TopNews, Examiner.com, and Canyon News.
New experimental test for prostate cancer more sensitive, specific than PSA test (study authors include Allan Pantuck, MD, MS, FACS). This study was covered by UCLA Newsroom.
UCLA researchers use 'nano-Velcro' technology to improve capture of circulating cancer cells (clinical trial team includes Matt Rettig, MD and Jiaoti Huang, MD, PhD). UCLA Newsroom and the Prostate Cancer Foundation covered this story.
